BioCentury
ARTICLE | Politics & Policy

CMTP names heads of trial standards consortia

November 22, 2013 1:24 AM UTC

The not-for-profit Center for Medical Technology Policy named the heads of two consortia developing disease-specific clinical trial standards based on payers' evidence expectations. The consortia are part of the Green Park Collaborative USA, which CMTP launched in May to guide the "generation of evidence needed to inform coverage and payment decisions" in the U.S.

Donna Messner, CMTP research director, will head a consortium developing guidance and data recommendations for studies on sequencing cancer care treatments. C. Daniel Mullins, a professor at the University of Maryland School of Pharmacy, will lead the second consortium, which is developing guidance on trials about real world effectiveness and outcomes in endocrine and metabolic diseases, with an initial focus on Type II diabetes medications. Both consortia will create working groups to develop guidance expected to be published next year. The consortia have about 50 members each, including industry and payer representatives as well as patient advocates, regulators, researchers and clinicians. CMTP is not providing a public list of the members. ...